Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection.
COVID-19
SARS-CoV-2
antigenemia
nucleocapsid
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
received:
16
03
2022
accepted:
08
06
2022
pubmed:
26
7
2022
medline:
4
11
2022
entrez:
25
7
2022
Statut:
ppublish
Résumé
Detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is essential for diagnosis, treatment, and infection control. Polymerase chain reaction (PCR) fails to distinguish acute from resolved infections, as RNA is frequently detected after infectiousness. We hypothesized that nucleocapsid in blood marks acute infection with the potential to enhance isolation and treatment strategies. In a retrospective serosurvey of inpatient and outpatient encounters, we categorized samples along an infection timeline using timing of SARS-CoV-2 testing and symptomatology. Among 1860 specimens from 1607 patients, the highest levels and frequency of antigenemia were observed in samples from acute SARS-CoV-2 infection. Antigenemia was higher in seronegative individuals and in those with severe disease. In our analysis, antigenemia exhibited 85.8% sensitivity and 98.6% specificity as a biomarker for acute coronavirus disease 2019 (COVID-19). Thus, antigenemia sensitively and specifically marks acute SARS-CoV-2 infection. Further study is warranted to determine whether antigenemia may aid individualized assessment of active COVID-19.
Identifiants
pubmed: 35877413
pii: 6649768
doi: 10.1093/infdis/jiac225
pmc: PMC9384592
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1577-1587Subventions
Organisme : NIBIB NIH HHS
ID : U54 EB027690
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI151788
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL069769
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM142617
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008169
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002378
Pays : United States
Organisme : NIH HHS
ID : U54 CA260563-01
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Déclaration de conflit d'intérêts
Potential conflicts of interest. C. A. R.’s institution has received funds to conduct clinical research unrelated to this work from BioFire Inc, GSK, MedImmune, Micron, Janssen, Merck, Moderna, Novavax, PaxVax, Pfizer, Regeneron, and Sanofi-Pasteur; she is coinventor of patented RSV vaccine technology unrelated to this work, which has been licensed to Meissa Vaccines, Inc. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
N Engl J Med. 2020 Dec 24;383(26):2586-2588
pubmed: 33259154
Viruses. 2022 Jul 28;14(8):
pubmed: 36016276
N Engl J Med. 2022 Jan 20;386(3):264-272
pubmed: 34995029
Clin Infect Dis. 2021 Aug 2;73(3):e815-e821
pubmed: 33507235
Nat Commun. 2021 Mar 26;12(1):1931
pubmed: 33771993
J Virol Methods. 2005 Dec;130(1-2):45-50
pubmed: 16024098
N Engl J Med. 2020 Nov 26;383(22):e120
pubmed: 32997903
Sci China Life Sci. 2021 Jul;64(7):1193-1196
pubmed: 33259038
Emerg Infect Dis. 2004 Nov;10(11):1947-9
pubmed: 15550204
Clin Microbiol Infect. 2020 Dec 8;:
pubmed: 33307227
Clin Chem. 2020 Dec 1;66(12):1562-1572
pubmed: 32897389
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
Science. 2021 Mar 12;371(6534):1139-1142
pubmed: 33536258
J Clin Microbiol. 2021 Sep 20;59(10):e0100121
pubmed: 34260271
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33468605
Clin Infect Dis. 2021 Nov 2;73(9):e3127-e3129
pubmed: 33570097
J Virol Methods. 2022 Apr;302:114469
pubmed: 35051445
N Engl J Med. 2022 Jan 27;386(4):305-315
pubmed: 34937145
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
Front Public Health. 2021 Mar 19;9:652842
pubmed: 33816427
Transfusion. 2021 Jun;61(6):1740-1748
pubmed: 34041759
Clin Chem. 2021 Dec 30;68(1):240-248
pubmed: 34358289
Front Cell Infect Microbiol. 2020 Sep 04;10:470
pubmed: 33014893
Clin Chem. 2021 Dec 30;68(1):204-213
pubmed: 34605900
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
Transfus Clin Biol. 2021 Feb;28(1):51-54
pubmed: 33096207
J Clin Microbiol. 2021 Oct 19;59(11):e0046921
pubmed: 34346713